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Figure 1. The average annual incidence of congestive heart failure 
for men and women at different ages. In all age groups there is a 
reduced incidence of the development of heart failure in women as 
compared with men. Reprinted with permission from McFate-Smith 
(2). 
prevalence of congestive heart failure have been increasing. 
These trends may be due, in part, to the aging population, 
and in part to the improvements in therapy that have allowed 
patients with cardiovascular disease to live longer, so that 
congestive heart failure becomes a more common clinical 
problem. 
Definition 
A traditional definition of congestive heart failure is “the 
inability of the heart to deliver enough blood to peripheral 
tissues to meet metabolic demands.” This definition, how- 
ever, does not fully describe the syndrome of congestive 
heart failure as we see it in clinical practice. The two major 
symptom complexes of congestive heart failure are dyspnea 
(particularly dyspnea with exercise) and fatigue. It is pre- 
sumed that these two major symptoms relate to the two 
major hemodynamic abnormalities of congestive heart fail- 
ure-namely, an increase in left atria1 pressure and a de- 
crease in cardiac output. Thus, from a functional viewpoint, 
it is clear that congestive heart failure also includes the 
symptoms of dyspnea and fatigue and a decrease in exercise 
tolerance. Therefore, there is not only a decrease in periph- 
eral blood flow to meet metabolic demands, but also an 
increase in atria1 pressures leading to the signs and symp- 
toms of either right or left heart failure, or both. 
Etiology 
In the Framingham study (7) which prospectively exam- 
ined the development of heart failure in a cohort of the 
population of Framingham, Massachusetts, it appeared that 
hypertension was one of the major factors leading to heart 
failure. Over the past 2 decades, however, better recognition 
and treatment of high blood pressure have reduced the 
relative importance of this factor. Certainly, better treatment 
of hypertension has dramatically reduced the incidence of 
stroke. In current series in the United States, it appears that 
in about 50 to 75% of patients with heart failure, coronary 
artery disease is the underlying cause (8). Hypertension may 
be a contributing factor in some patients, but is clearly less 
important than myocardial infarction and ischemia. The next 
most common cause appears to be cardiomyopathy. Rheu- 
matic heart disease is declining significantly in the United 
States, although valvular heart disease due to mitral regur- 
gitation or aortic stenosis is still reasonably common in the 
population at large. Congenital heart disease represents only 
a small portion of patients presenting with congestive heart 
failure. 
General Principles 
When a patient presents with the signs and symptoms of 
congestive heart failure it is important that the etiology of 
this syndrome be carefully identified. In addition to history 
and physical examination, echocardiography and other non- 
invasive and invasive tests can be very helpful in assessing 
the precise cause of the congestive heart failure. It is also 
important to determine whether the signs and symptoms are 
due primarily to ventricular systolic dysfunction, diastolic 
dysfunction or a combination of the two. In most cases 
systolic dysfunction, as manifested by a decreased ejection 
fraction, will be the most common cause of congestive heart 
failure. In a minority of cases, diastolic dysfunction will be 
the predominant cause (9). The latter circumstances would 
include patients with hypertrophic cardiomyopathy, hyper- 
trophy from any cause, restrictive cardiomyopathy, pericar- 
dial disease, certain infiltrative diseases such as amyloid or 
any process that impedes filling of the ventricle and thus 
leads to an increase in atria1 pressures when cardiac output 
is increased. It is likely that almost all patients who have 
systolic dysfunction have some element of diastolic dysfunc- 
tion as a contributing cause. Our inability to effectively treat 
diastolic dysfunction, however, limits our ability to provide 
major therapeutic benefit to patients with this disorder. 
Certainly if patients have constrictive pericarditis, removal 
Figure 2. Survival curves of men and women after the onset of 
congestive heart failure (CHF) in the Framingham study. The data 
are compared with the total population sample at the top of each 
graph. The survival of women is higher than that of men throughout 
the follow-up. Reprinted with permission from Stamler (4). 
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of the pericardium can be quite dramatic in improving 
function. Similarly, valvotomy in patients with mitral steno- 
sis can also produce a dramatic benefit in what is primarily a 
filling problem of the left ventricle. Some patients with 
severe hypertrophic cardiomyopathy may benefit from cal- 
cium channel blocker therapy, which can increase left ven- 
tricular volume at the same end-diastolic pressure (10). 
Similarly, in patients with severe hypertensive hypertrophy, 
which may restrict ventricular filling, control of hyperten- 
sion with antiadrenergic drugs, the angiotensin-converting 
enzyme inhibitors or calcium channel blockers can cause 
regression of the hypertrophy (11) and thus reduce diastolic 
dysfunction. It is clear, however, that we need to learn much 
more about diastolic dysfunction and ways to alter it to 
effectively treat this component of congestive heart failure. 
Our current understanding of congestive heart failure is 
based on our understanding of changes that occur in the 
myocardium as well as peripheral changes, including neuro- 
humoral alterations, that affect the circulation. These 
changes will be described in the next sections. 
Decrease in Myocardial Contractility 
A fundamental problem for patients with systolic dys- 
function is a decline in myocardial contractility. This can be 
the result of prolonged pressure or volume overload or an 
intrinsic decline associated with cardiomyopathy. In patients 
with ischemic heart disease, loss of muscle with myocardial 
infarction imposes an additional volume and wall stress 
overload on the remaining normal myocardium. These 
changes lead to remodeling of the ventricle over time and, 
eventually, to a similar intrinsic decline in contractility. In 
general, therefore, therapy has been directed toward earlier 
recognition and treatment of increased loading conditions of 
the ventricle. For example, angiotensin-converting enzyme 
inhibitors may prevent remodeling and delay or attenuate the 
irreversible decline in contractility that occurs with in- 
creased loading after myocardial infarction (12). 
Indexes of reduced muscle contraction. A reduction in 
myocardial contractility is manifested by decreased force 
development, decreased rate of force development and 
decreased velocity of shortening at given loading conditions. 
These changes are frequently accompanied by a delay in 
relaxation (Table 1). These indexes of muscle contraction 
(13) are reflected in the intact heart by a decrease in ejection 
fraction and stroke volume and by a shift downward in the 
ventricular function curve with an increase in atria1 pressure. 
Biochemical changes. A number of biochemical changes 
have been noted to accompany the process of congestive 
heart failure. Although it is outside the scope of this review 
to examine all of these, a few are listed in Table I. A 
reduction in contractility is frequently accompanied by a 
shift in myosin isozymes, such that rapidly contracting V, 
forms with high adenosine triphosphatase (ATPase) activity 
Table 1. Myocardial Changes in Congestive Heart Failure 
Mechanical 
I, Decreased force development 
2. Decreased rate of force development 
3. Decreased velocity of shortening 
4. Delayed relaxation 
Biochemical 
I. Shift in myosin isozymes 
2. Hypertrophy and increase in connective tissue 
3. Calcium overload 
4. Decreased function of sarcoplasmic reticulum 
5. Decreased stores of myocardial norepinephrine 
6. Decreased production of norepinephrine 
7. Decreased beta-receptors 
are converted into slower contracting V, forms with slower 
ATPase activity (14). The relation between maximal velocity 
of shortening and myosin ATPase activity seen over a wide 
variety of species (15) also occurs in animal models of 
congestive heart failure and in patients. A reduction in 
velocity of shortening and actomysin ATPase activity has 
the potential benefit of reducing oxygen consumption and 
thus conserving energy in circumstances where it may be 
limited. Clearly, however, this compensatory aspect does 
not make up for the dramatic reduction in function that leads 
to reduced cardiovascular performance. 
Hypertrophy is one of the most important compensatory 
mechanisms available to heart muscle as function decreases, 
and it is accompanied by an increase in connective tissue 
that may stiffen the diastolic properties of the heart (16). In 
animal models of heart failure, calcium overload may play an 
important role in the development of congestive heart failure 
(17). This may occur through damage of the sarcolemma or 
perhaps through increased calcium entry due to increased 
sympathetic tone or increased sodium-calcium exchange. 
Certainly, the sarcoplasmic reticulum exhibits decreased 
function (18). An excess of myoplasmic calcium can reduce 
mitochondrial function and decrease the production of high 
energy phosphates. At least in animal models of congestive 
heart failure, such as the hereditary cardiomyopathy of the 
Syrian hamster, calcium overload plays a major role (19). 
The calcium channel blocker, verapamil, is effective in 
attenuating or treating this form of experimental heart fail- 
ure. Microvascular spasm (20) has also been implicated in 
some experimental models of congestive heart failure and 
has responded to a vasodilator, such as prazosin (21). It is 
not clear, however, whether these specific biochemical 
changes in experimental models of heart failure have any 
application to the clinical syndrome of congestive heart 
failure. 
Sympathetic nervous system and neuroendocrine activity. 
The activity of the sympathetic nervous system is increased 
in congestive heart failure (22). A reflex increase in sympa- 
thetic tone is presumably designed to maintain cardiovascu- 
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lar compensation by increasing heart rate and contractility. 
This increased tone leads to a decline in stores of norepi- 
nephrine in the myocardium (23) that spill over into the 
circulation. In some animal species there is also a decline in 
the production of norepinephrine (24). Increased catechol- 
amines lead to a decline in beta,-receptors (25), although 
beta,-receptors may be little affected. These latter changes 
reduce the responsiveness of the myocardium to catechol- 
amines, but the marked increase in plasma catecholamines in 
congestive heart failure is still sufficient to produce impor- 
tant sympathetic support of the circulation. Some studies in 
dilated cardiomyopathy suggest that this increased sympa- 
thetic drive may actually be deleterious. Some patients with 
dilated cardiomyopathy have responded beneficially to low 
dose metoprolol (26); this finding suggests that excess sym- 
pathetic drive may be directly harmful to the heart. Certainly 
high dose catecholamine infusions can directly cause myo- 
cardial necrosis in experimental animals (27). The combina- 
tion of tachycardia and prolonged sympathetic stimulation 
may be deleterious in some patients with congestive cardio- 
myopathy. Tachycardia in and of itself not only increases 
myocardial oxygen demand, but also, by reducing diastolic 
time, can reduce coronary blood flow to the myocardium and 
contribute to an imbalance between supply and demand. 
Although beta-blocker therpay may be benejicial for 
some patients with cardiomyopathy, it is clear that it does 
not have widespread application to all forms of heart failure. 
In fact, beta-blockade can suddenly and dramatically worsen 
function in some patients who have severe congestive heart 
failure. The precise role, therefore, of the sympathetic 
nervous system and its potential benefit and harm have yet 
to be firmly elucidated in different patient subsets. 
Pressure and volume overloading. If increased loading 
factors are deleterious to heart muscle, it is clear that 
unloading therapy may be one of the most beneficial ways to 
attenuate the adverse effects of prolonged pressure or vol- 
ume overloading. In general, the decline in contractility that 
accompanies severe heart failure appears to be mostly 
irreversible and to continue in a downward spiral. Relief of 
pressure or volume overload in circumstances of valvular 
disease, however, has shown that there can be some resti- 
tution of function (28). This emphasizes the importance of 
earlier intervention before these irreversible changes pro- 
duced by pressure and volume overloading cause an irre- 
versible decline in cardiac contractility. 
Neurohormonal and Other Peripheral 
Factors in Congestive Heart Failure 
Increased sympathetic nerve reflexes and plasma catechol- 
amines. A number of neurohormonal factors contribute to 
the syndrome of congestive heart failure. Three hormonal 
systems that are activated in congestive heart failure include 
the renin-angiotensin-aldosterone system (29), the sympa- 
Table 2. Neurohormonal and Peripheral Changes in Congestive 
Heart Failure 
Neurohormonal 
1. Increased plasma catecholamines 
2. Activation of renin-angiotensin-aldosterone system 
3. Increased arginine vasopressin (antidiuretic hormone) 
4. Increased atrial naturetic factors 
Peripheral factors 
1. Increased systemic vascular resistance 
2. Blunting of baroreceptor reflexes 
3. Decreased vasodilatory response of peripheral vasculature 
4. Altered regional flows 
5. Venoconstriction 
thetic nervous system (22) and arginine vasopressin (antidiu- 
retie hormone) (30). The marked increased in catechol- 
amines is probably a reflection of the overall severity of the 
heart failure state (31), because it is presumed that this 
increase in sympathetic tone is intended to be compensa- 
tory. For example, the decrease in stroke volume and 
cardiac output that accompanies heart failure leads to a 
decrease in arterial pressure. The baroreceptor-mediated 
reflex increase in systemic vascular resistance produced by 
an increase in sympathetic tone would initially be helpful in 
maintaining arterial pressure during a decrease in cardiac 
output. Similarly, the decline in contractility that occurs in 
heart failure would be supported by the increased activity of 
the sympathetic nervous system, which could thus help to 
maintain stroke volume and cardiac output. Not only is there 
an increase in plasma catecholamines, but also there is an 
abnormal response of the sympathetic nervous system to 
physiologic interventions. Some examples are listed below. 
When patients with heart failure are subjected to upright tilt, 
there may be no change in plasma norepinephrine, although 
in normal subjects there would be an increase in plasma 
norepinephrine levels (32). This blunting of baroreceptor 
responses appears to form a component of the heart failure 
syndrome (33). Whether this is due to a smaller reduction in 
atria1 pressures, changes in afferent stimulation or changes in 
central integration is not clear. Increasing or decreasing 
arterial pressures also does not produce the same respon- 
siveness in patients with congestive heart failure. During 
exercise there may be a more abrupt increase of plasma 
norepinephrine at lower work loads in patients with failure, 
although the relative change in plasma norepinephrine may 
be less appropriate to the maximal achievable exercise 
response (34). Thus, overall there may be some blunting of 
the catecholamine response to exercise. 
The arginine vasopressin system. This system is also 
increased in most patients with congestive heart failure (30). 
Because this antidiuretic hormone is such a potent vasocon- 
strictor, it could contribute to the peripheral vasoconstric- 
tion which can be so deleterious to patients with severe heart 
failure. Studies (35) suggest that osmoreceptor function is 
JACC Vol. 13, No. 4 PARMLEY 
March IS, 1989:771-X5 PATHOPHYSIOLOGY AND THERAPY OF HEART FAILURE 
775 
essentially intact in patients with congestive heart failure. In 
a few patients, arginine vasopressin may directly contribute 
to adverse sympathetic tone. 
Atria1 natriuretic hormones. Patients with heart failure 
generally have higher levels of atria1 natriuretic factor than 
do normal persons (36). Data suggest that the effects of atria1 
natriuretic factor on diuresis are diminished in patients with 
congestive heart failure. Although infusion of this hormone 
has produced increases in cardiac output and increased renal 
excretion (37), it is unclear that this will be a major thera- 
peutic intervention in relation to all of the other drugs 
available in patients with congestive heart failure. 
The renin-angiotensin-aldosterone system. This system is 
also activated in patients with congestive heart failure (29). 
The three primary mechanisms whereby renin increase is 
promoted include reduced serum sodium, an increase in 
sympathetic tone and decreased blood pressure perfusing 
the macula densa. All three of these factors are frequently 
present in patients with congestive heart failure. Further- 
more, diuretic usage is extremely common in such patients 
and may contribute directly to the observed rise in renin 
activity in this group. Renin, in turn, converts an angioten- 
sinogen made in the liver to angiotensin 1. which is an 
inactive decapeptide. Angiotensin I is then converted to 
angiotensin II by converting enzyme. Converting enzyme is 
located everywhere in the body but appears to predominate 
in pulmonary capillary endothelial cells. 
Angiotensin II has three effects that may be deleterious to 
patients with congestive heart failure. First, it is a potent 
vasoconstrictor that may contribute to excess systemic vas- 
cular resistance. Second, it tends to facilitate sympathetic 
outflow that may contribute to the already elevated levels of 
plasma catecholamines. Third, it feeds back on the adrenal 
gland to release aldosterone and thus further contributes to 
the increased salt retention seen in patients with heart failure. 
Patients with a low serum sodium level appear to have the 
highest renin levels (38). They are also the patients who have 
the highest mortality rate (39) and may be the most respon- 
sive to the angiotensin-converting enzyme inhibitors. 
Antagonists to the three neurohormonal systems. The rel- 
ative importance of the three vasoconstrictor hormone sys- 
tems was evaluated in a study by Creager et al. (40) (Fig. 3). 
In that study, patients were given antagonists to the three 
neurohormonal systems to counteract their vasoconstric- 
tion. The resultant hemodynamic response, therefore, rep- 
resents the ability to reverse the adverse hemodynamic 
effects of these systems. On average, the antagonist to 
arginine vasopressin produced only minimal hemodynamic 
changes. Captopril, which interferes with the renin- 
angiotensin system, produced moderate beneficial hemody- 
namic effects, including an increase in cardiac output and a 
reduction in filling pressures. The greatest changes in hemo- 
dynamics were produced by an alpha-adrenergic blocker 
(phentolamine), which antagonized the peripheral vasocon- 
-40 
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Figure 3. Effects of antagonists to three neurohormonal systems in 
patients with congestive heart failure. The percent change in hemo- 
dynamic values is shown with the administration of the three 
antagonists. The percent change was least with the arginine vaso- 
pressin (AVP) antagonist and greatest with the alpha-adrenergic 
blocker, phentolamine. Changes with captopril were intermediate. 
See text for discussion. Reprinted with permission from Creager et 
al. (40). BP = blood pressure; CI = cardiac index; HR = heart rate; 
LVFP = left ventricular filling pressure; RAP = right atrial pres- 
sure: SW = stroke volume index: SVR = systemic vascular 
resistance. 
strictive effects of increased catecholamines. This produced 
the greatest change in forward cardiac output and the 
greatest reduction in filling pressures. These findings suggest 
that the relative effects of vasoconstriction are produced in 
order by 1) excess sympathetic stimulation and catechol- 
amines, 2) the renin-angiotensin-aldosterone system, and 3) 
the arginine vasopressin system. 
Peripheral vascular changes: alterations in regional flow. 
Several peripheral vascular changes accompany the heart 
failure state. In addition to the increase in systemic vascular 
resistance, some studies (41) have suggested that there is an 
inability of the peripheral vasculature to dilate normally in 
response to stimuli such as hyperemia after transient vascu- 
lar occlusion. A blunting of the baroreceptor mechanism has 
also been found and may explain why some vasodilator 
drugs do not result ‘in an increase in heart rate in the same 
way that they do in patients with normal ventricular func- 
tion. A limitation of cardiac output requires that regional 
flows be preserved for vital organs such as the heart and 
brain, whereas there may be a substantial reduction of the 
circulation in the skin, splanchnic bed, skeletal muscle and 
kidney (42). These alterations in regional flow may contrib- 
ute greatly to some of the associated signs and symptoms 
accompanying severe congestive heart failure. In addition to 
arteriolar vasoconstriction, there is also venoconstriction 
especially due to increased catecholamines. 
Compensatory Mechanisms 
The four primary determinants of cardiac function are 
preload, afterload, contractility and heart rate. There is 
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Figure 4. Two interrelated vicious cycles in congestive heart fail- 
ure. Left panel, the impairment of left ventricular (LV) function 
leads to a decrease in cardiac output. In turn, this leads to a reflex 
increase in systemic vascular resistance by the neurohormonal 
mechanisms that were described in Figure 3. This in turn, increases 
the effective afterload of the left ventricle and further reduces stroke 
volume. Right panel, a reduction in cardiac output and arterial 
pressure leads to a decrease in renal perfusion. This activates the 
renin-angiotensin-aldosterone system. Overall, there is retention of 
salt (NaCl) and water (H,O) leading to a further increase in filling 
pressure and to peripheral edema. These vicious cycles therefore 
can feed back on each other to worsen the heart failure state. 
Reprinted with permission from McCall et al. (43). 
evidence that each of these mechanisms may provide some 
compensation for the failing circulatory system, especially 
early in its course. An important concept, however, devel- 
oped over the past decade, is that these compensatory 
mechanisms can overshoot and become deleterious (43). 
Overshoot of compensatory mechanisms. The increase in 
extracellular volume that occurs through retention of sodium 
and water is initially helpful in augmenting preload and thus 
increasing stroke volume by the Frank-Starling mechanism. 
Clearly, this mechanism overshoots when increased atria1 
pressures produce pulmonary or systemic congestion, or 
both. This overshoot then must be appropriately treated with 
diuretics or venodilators, or both. An increase in systemic 
vascular resistance, as an index of afterload, is initially 
helpful in maintaining blood pressure despite a decrease in 
cardiac output. It is clear, however, that this increase in 
systemic vascular resistance may eventually become harm- 
ful as shown by the beneficial effects of arteriolar vasodila- 
tors that can dramatically increase forward cardiac output. It 
is also clear that an increase in contractility can be beneficial 
in maintaining cardiac function. The increase in catechol- 
amines that is required to produce this increase in contrac- 
tility, however, may be too great and produce damage to 
heart muscle and result in arrhythmias. Heart rate is one of 
the most important compensatory mechanisms available to 
the circulation. With a decline in stroke volume, an increase 
in heart rate is essential to maintain a reasonably normal 
cardiac output. As heart rate increases, however, not only 
does it increase myocardial oxygen demand but also it 
impinges on diastolic time during which coronary flow can 
occur. Excess tachycardia, therefore, may contribute di- 
rectly to continuing cardiac damage, by causing an imbal- 
ance between myocardial oxygen supply and demand. 
Deleterious vicious cycles contributing to heart failure. 
This overshoot in compensatory mechanisms can produce 
vicious cycles such as those illustrated in Figure 4. The 
decline in cardiac contractility leads, by potent neuro- 
humoral mechanisms, to an increase in systemic vascular 
resistance. This increased resistance can act as an increased 
afterload and impedance to ejection, and thus further reduce 
cardiac output. The downward spiral continues until a new 
low steady state level is reached at which cardiac output is 
lower and systemic resistance higher than is optimal for the 
circulation. Similarly, a reduction in cardiac output contrib- 
utes to decreased renal perfusion, which also leads to an 
increase in salt and water retention. In excess, this can also 
worsen the heart failure state and contribute to a further 
downward spiral. It is clear that a complex interaction of a 
number of factors contributes to the development of heart 
failure. It is therefore possible for a variety of interventions 
to counteract the overshoot and thus beneficially affect 
cardiac function. 
Therapeutic Approach to Congestive Heart 
Failure (Table 3) 
After one has identified the syndrome of congestive heart 
failure, it is mandatory to determine its cause and to assess 
the relative contribution of diastolic dysfunction. These 
steps may indicate the need for therapeutic interventions 
apart from the pharmacologic treatment to be described 
later. For example, patients with severe aortic stenosis need 
replacement of the aortic valve. Similarly, patients with 
other types of valvular disease may be benefited by appro- 
Table 3. Therapeutic Approach to Congestive Heart Failure 
1. Determine the etiology 
2. Evaluate relative importance of diastolic dysfunction 
3. Surgical correction where possible 
4. Nonpharmacologic treatment 
A] Reduce salt intake; avoid salt excess 
B) Reduce physical and emotional stress 
5. Pharmacologic approach 
A) Either diuretic, digoxin or vasodilator as first line therapy 
B) Add second and third drugs as necessary 
C) Vasodilators are generally used because they can prolong life 
1) ACE inhibitors 
2) Combination of hydralazine and isosorbide dinitrate 
D) Add potent inotropic agents if the above is ineffective 
I) Intermittent dobutamine 
2) Phosphodiesterase inhibitors 
E) For dilated cardiomyopathy consider low dose metoprolol 
6. Consider heart transplant for appropriate patients with end-stage heart 
failure 
ACE = angiotensin-converting enzyme. 
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priate valve replacement or repair. In patients in whom 
ischemia is an important factor, revascularization proce- 
dures or antiischemic therapy may be of great benefit in 
alleviating some of the signs and symptoms of congestive 
heart failure, especially those that are transient and due to 
intermittent myocardial ischemia. 
Nonsurgical, nonpharmacologic approaches. In some pa- 
tients who do not need (or cannot undergo) surgical correc- 
tion, a variety of nonpharmacologic approaches should be 
considered. Reduction of the work load of the heart by 
reducing overall activity, including both emotional and phys- 
ical stress, can be of great benefit to some patients. Salt 
restriction and avoidance of salt overload can be useful in 
patients who are prone to retention of fluid and whose 
symptoms appear to be closely linked to an increase in 
extracellular volume. A number of specific, although rare, 
circumstances must also be addressed. For example, hyper- 
thyroidism can contribute dramatically to deterioration in 
patients who have an underlying cause for heart failure. 
Similarly, anemia and other causes of high cardiac output 
(44) may contribute to the borderline compensation seen in 
some patients. When attention has been paid to these 
nonpharmacologic approaches to therapy, one can then 
consider the use of drugs from the three major classes of 
antifailure drugs now available-the diuretics, inotropic 
agents and vasodilator drugs. These will be discussed in the 
sections that follow. 
Diuretics 
Under normal circumstances, renal plasma flow is ap- 
proximately 10% of the cardiac output and thus is about 500 
mlimin (45). When mean arterial pressure ranges from about 
80 to 200 mm Hg, glomerular filtration rate is kept approxi- 
mately constant by autoregulation. Below these levels, how- 
ever, renal blood flow is decreased as arterial pressure is 
decreased and glomerular filtration may stop at an arterial 
pressure of about 40 mm Hg. In general, about 20% of the 
plasma that enters the glomerulus is filtered and, as an end 
result, about 1% of the filtrate is excreted in the urine. In 
patients with congestive heart failure, there is a reduction in 
cardiac output and arterial pressure. The renal response to 
this hemodynamic change is retention of salt and water. This 
has led to the use of diuretics as the most practical way of 
improving diuresis. Not only can diuretics be effective in 
increasing salt and water excretion, but, for example, when 
given intravenously, furosemide directly increases venous 
capacitance and can acutely reduce left ventricular filling 
pressure by redistributing blood away from the chest (46). 
Choice of diuretic. It is reasonable to begin treatment of 
congestive heart failure with a thiazide diuretic. Usually, 
however, a more potent loop diuretic will eventually be 
needed by patients who have at least moderate heart failure. 
Attention must be paid to electrolyte imbalance in patients 
with congestive heart failure because hypokalemia and hy- 
pomagnesemia can lead to serious arrhythmias, especially in 
patients who are taking digitalis. Potassium supplementation 
is frequently required in patients with congestive heart 
failure who are taking potent diuretics. Alternatively, a 
potassium-retaining diuretic might be considered. It should 
be remembered, however, that the angiotensin-converting 
enzyme inhibitors retain potassium. Therefore, it is impor- 
tant to discontinue potassium-retaining diuretics and potas- 
sium supplementation in patients receiving angiotensin- 
converting enzyme inhibitors. In patients who become 
refractory to loop diuretics, one may get additional benefit 
by adding a thiazide such as metolazone (47). The fact that 
the two classes of diuretics work at different places in the 
nephron appears to explain their synergistic effect, which 
may be quite dramatic in some patients. 
Clinical effect. Long-term experience has shown that 
diuretics can be extremely effective in some patients with 
congestive heart failure. They certainly are required in 
patients whose peripheral edema and excess fluid retention 
become major components of the syndrome of heart failure. 
Although we have no firm data suggesting that diuretics can 
prolong life in patients with heart failure, it is intuitive that 
these agents have been beneficial in alleviating symptoms 
and. in some circumstances, had the appropriate studies 
been done, they might have been found to have contributed 
to longevity. 
Digitalis 
Inotropic Agents 
The most commonly used inotropic agent is digitalis. 
Numerous questions have arisen over the past few years 
about the potential benefit of digitalis and have probably led 
to a decline in its use, particularly in the United Kingdom. In 
the United States, however, digitalis is still a commonly used 
agent. It is effective in patients who have atria1 fibrillation 
and a rapid ventricular response. A reduction in the ventric- 
ular rate. together with a positive inotropic effect, are 
generally quite beneficial in these patients. The greatest 
controversy, however, has arisen about the use of digitalis in 
patients with congestive heart failure and sinus rhythm. In 
some studies of such patients discontinuation of digitalis 
produced no detrimental effects (48,49). In other studies of 
such patients (50) the patients’ heart failure clearly deterio- 
rated (50) after withdrawal of digitalis. In a double blind 
placebo-controlled crossover study. Lee et al. (51) compared 
the effects of digoxin and placebo in 25 outpatients with 
sinus rhythm. In general, there was benefit in patients with a 
dilated heart, a reduced ejection fraction and a third sound 
gallop. Other studies with digitalis have also suggested that 
this drug may be more beneficial in sicker patients as 
compared with patients with mild heart failure. Dobbs et al. 
(52) reported a double blind crossover comparison of digi- 
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talis versus placebo in 46 patients with sinus rhythm. Ap- 
proximately 33% of the patients receiving placebo showed 
deterioration that was followed by improvement after the 
reintroduction of digitalis therapy. 
Clinical application. Overall, the data suggest that digi- 
talis has modest beneficial effects in patients with congestive 
heart failure (53) and that these effects are probably of 
greater benefit as the heart failure becomes worse. Certainly, 
it has no benefit in patients with diastolic dysfunction when 
ejection fraction is preserved. It must also be used with 
caution in elderly patients, in whom toxicity may be a 
greater problem. Dose-response relations must be carefully 
considered as renal function becomes impaired because 
digoxin is cleared primarily by the kidney. Within these 
constraints, however, it appears that digoxin still has value 
in patients with sinus rhythm and congestive heart failure. 
Toxicity and mortality. Some studies (54,55), however, 
have suggested that patient mortality may be increased by 
the administration of digoxin, especially after myocardial 
infarction. Other studies (56) in patients with coronary artery 
disease have not confirmed this finding. Nevertheless, the 
known toxicity of this agent raises important questions about 
its long-term effects. A proposed multicenter study to assess 
the effect of digoxin on mortality in congestive heart failure 
will soon be underway to provide a more definitive answer to 
this question. Until that time, however, it appears reason- 
able to consider digoxin for its modest inotropic support to 
the heart in an appropriate clinical setting. 
Combination therapy. More recent studies have raised 
the question as to whether or not vasodilator therapy might 
be appropriately started before digoxin therapy. In the 
recent captopril-digoxin study (57), captopril was more 
effective in increasing exercise tolerance than was digoxin, 
whereas digoxin was more effective in increasing ejection 
fraction than was captopril. This study suggests that one can 
consider all three classes of drugs as initial therapy for heart 
failure. Thus, depending on the individual patient, one might 
want to begin treatment with a diuretic, an inotropic agent 
like digitalis or a vasodilator drug. Combination therapy may 
be more effective than either class alone. 
Phosphodiesterase Inhibitors 
There has been considerable interest in the phosphodies- 
terase inhibitors, which are potent inotropic agents and 
vasodilators (58). Inhibition of phosphodiesterase leads to an 
increase in cyclic adenosine monophosphate (AMP), which 
enhances calcium entry and thus improves contractility. 
These agents are also potent peripheral vasodilators, and 
produce significant hemodynamic effects in patients with 
heart failure. When given on a short-term basis to patients 
with heart failure, they result in an increase in cardiac output 
and a reduction in atria1 pressures (59). Similarly, exercise 
tolerance is increased acutely in most studies (60). Despite 
these short-term beneficial effects, however, these drugs 
(amrinone and milrenone) are not yet available for oral use in 
the United States. Part of the uncertainty regarding their use 
relates to the long-term effects of these agents, both on 
exercise tolerance and on mortality (61). Until appropriate 
studies can clearly define a long-term clinical benefit or a 
reduction in mortality, these agents are best reserved for 
patients who have not responded in a beneficial fashion to 
usual therapy but continue to require some pharmacologic 
support to maintain an appropriate quality of life or to 
remain outside of the hospital. 
Oral Catecholamines 
A number of oral catecholamines have been used in 
patients with heart failure; these include L-dopa, pirbuterol, 
prenalterol and salbutamol (62-65). It appears that these 
agents can produce short-term beneficia! hemodynamic ef- 
fects. However, a high side effect profile and problems with 
arrhythmias and potential sudden death have raised serious 
questions about the use of such agents in patients with 
congestive heart failure. Intermittent dobutamine in some 
controlled studies (66) has shown prolonged benefit in such 
patients. Short-term infusions for 24 to 72 h have been 
shown to improve both exercise time and ejection fraction 
over a subsequent period up to 4 weeks. Although the 
mechanism of this benefit is unclear, a potential training 
effect has been implicated as has an improvement in mito- 
chondrial function. A recent multicenter study of patients 
with heart failure treated at home with dobutamine was 
stopped because of an increase in serious arrhythmias in the 
treated group. It appears, therefore, that this form of therapy 
is best administered in a controlled hospital setting. 
Overall, it is clear that inotropic agents are much like a 
double-edged sword; although they can increase hemody- 
namics and exercise tolerance, their other effects may be 
potentially harmful to the patient. These include an increase 
in oxygen consumption, the generation of arrhythmias and 
the potential for more rapid deterioration of muscle function. 
It is less certain, therefore, about the long-term role of 
potent inotropic agents in the management of severe heart 
failure. 
Vasodilator Drugs 
Arteriolar Vasodiiators 
Hydralazine. As illustrated in Figure 4, a major compo- 
nent of the vicious cycle in congestive heart failure is an 
excess increase in systemic vascular resistance. This in- 
crease sets the stage for arteriolar vasodilators, which can 
decrease systemic resistance and increase cardiac output. 
Hydralazine is the prototypic agent that has been used in this 
regard. When administered to patients with severe conges- 
tive heart failure, hydralazine increases cardiac output ap- 
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proximately 50% in association with a concomitant reduc- 
tion in systemic vascular resistance (67). In general, there is 
little change or a slight decrease in atrial pressures with 
hydralazine therapy. This pharmacologic result underscores 
the reality of the vicious cycle in congestive heart failure, 
where neurohumoral mechanisms have overshot in their 
compensatory response and set systemic vascular resistance 
too high. On the other hand, it is clear that this increase in 
cardiac output may not necessarily be directed to organs that 
need it. For example, in a placebo-controlled trial (68) 
examining the effects of hydralazine on exercise tolerance, 
hydralazine or placebo was given to patients with moderate 
heart failure already receiving digitalis and diuretics. Over 
several weeks there was a slight improvement in the exercise 
tolerance of the hydralazine-treated patients, but it was no 
greater than the improvement in exercise tolerance seen in 
the patients receiving placebo. Thus, this arteriolar vasodi- 
lator was effective in increasing cardiac output but ineffec- 
tive in improving exercise tolerance. 
Hydralazine has been used with some effectiveness, 
however, in unloading the ventricle in patients with volume 
overload due to valvular regurgitation (69). Hydralazine is 
effective in both mitral and aortic regurgitation in this regard. 
In patients who are still asymptomatic but with moderate 
volume overload due to valvular regurgitation, it seems 
intuitive that, if one could unload the ventricle, one might 
delay the rate at which the ventricle dilates and therefore 
delay the onset of irreversible changes in ventricular func- 
tion. 
In patients with aortic regurgitation it appears that hy- 
dralazine may be of some benefit in this regard (70). It should 
be emphasized, however, that unloading therapy should 
never act as a substitute for surgical replacement of the 
valve. When severe changes in contractility occur, they 
appear to be mostly irreversible. 
The effective dose of hydralazine is generally between 200 
to 300 mglday given in divided doses. Hydralazine is metab- 
olized by acetylation. Approximately 50% of the United 
States population are rapid acetylators and half are slow 
acetylators. In rapid acetylators, higher doses of hydralazine 
may be required. Similarly, the lupus syndrome tends to 
occur primarly in patients who are slow acetylators. The 
primary side effects of hydralazine are related to the gastro- 
intestinal tract and require discontinuation of this drug in a 
fair proportion of patients. 
Minoxidil. Another potent arteriolar vasodilator that has 
been evaluated in congestive heart failure is minoxidil, 
which is approved for the treatment of resistant hyperten- 
sion. The hemodynamic effects of minoxidil are similar to 
those of hydralazine (71). The drug produces a substantial 
increase in cardiac output, together with a minor decrease in 
atria1 pressures. In a placebo-controlled trial (72), however, 
minoxidil did not increase exercise tolerance as compared 
with placebo. Side effects included sodium retention and hair 
growth, the latter being quite troublesome to female pa- 
tients. Results with these two arteriolar vasodilators suggest 
a simple but important principle. namely, that arteriolar 
vasodilators do not increase exercise tolerance, although 
they are effective in increasing cardiac output. 
Venodilators 
Nitrates. Nitrates are the prototypic venodilators (73); 
they are available in many preparations, including sublingual, 
oral and transdermal. If given in effective doses, they can 
reduce atria1 pressures, presumably by dilating peripheral 
veins and redistributing blood so that more is in the peripheral 
veins and less in the chest. When nitrates are given to 
individuals with normal filling pressures, filling pressures 
frequently become too low and hypotension and tachycardia 
result. In patients with congestive heart failure, however, this 
is not a problem. Nitrates generally do not produce tachycar- 
dia in patients with congestive heart failure. 
The nitrates have produced an improvement in exercise 
tolerance in patients with congestive heart failure, as com- 
pared with those receiving placebo (74,75). This appears to 
be true of virtually all agents that lower atria1 pressures. 
Thus, venodilators that lower atria1 pressures not only are 
effective in relieving dyspnea, but also are effective in 
improving exercise tolerance in patients with congestive 
heart failure. 
Combination therapy. The fact that arteriolar vasodila- 
tors can increase cardiac output and that venodilators can 
reduce filling pressures has led to their combined use in 
patients with congestive heart failure (76). This combination 
was able to prolong life in patients with moderate heart 
failure in the V-HEFT trial (77). This trial was the first trial 
to demonstrate that vasodilator therapy could prolong life in 
patients with congestive heart failure and therefore becomes 
a landmark trial in encouraging physicians to use vasodila- 
tors relatively commonly in the management of patients with 
congestive heart failure. 
Nitrate dosage and administration. The usual doses of 
isosorbide dinitrate range from 20 to 80 mg four times daily. 
Patches are generally ineffective at usual doses (78) and, 
even when they are given at high doses, one must employ a 
nitrate free interval to retain responsiveness to the drug. 
Shorter-acting forms of nitrates such as sublingual nitroglyc- 
erin can be effective for short-term episodes of dyspnea or 
ischemia. Nitroglycerin ointment can be effective in some 
patients whose dyspnea occurs primarily during the sleeping 
hours. 
Drugs With Combined Arteriolar arid 
Venodilating Effects 
Prazosin. The prototypic drug in this category is prazo- 
sin, which is an alpha, receptor blocker and can produce 
780 PARMLEY 
PATHOPHYSIOLOGY AND THERAPY OF HEART FAILURE 
JACC Vol. 13, No. 4 
March 15, 1989:771-85 
0.8 
1 0.7 
Figure 5. Cumulative total mortality in the CONSEN- 
SUS trial. The enalapril-treated patients showed a sta- 
tistically significant reduction in mortality as compared 
with placebo-treated patients. This was most marked in 
the first 3 months, with the curves remaining relatively 
parallel thereafter. Reprinted with permission from the 
CONSENSUS Trial Study Group (85). 
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both arteriolar and venous dilation (79). Studies with prazo- 
sin have shown that it can reduce filling pressures and 
increase cardiac output, and thus produce the same hemo- 
dynamic effects as those of combined hydralazine and iso- 
sorbide dinitrate. Unfortunately, there appears to be a 
hemodynamic tachyphylaxis with prazosin, such that there 
are no sustained long-term effects (80). This may explain 
why prazosin was ineffective in the V-HEFT trial in prolong- 
ing life compared with placebo (77). Because of this hemo- 
dynamic tachyphylaxis and inability to prolong life, prazosin 
does not appear to have a role in the management of 
congestive heart failure as compared with the combination of 
hydralazine plus isosorbide dinitrate, and the angiotensin- 
converting enzyme inhibitors. 
Angiotensin-Converting Enzyme Inhibitors 
Captopril, enalapril and lisinopril. These agents have 
been extremely effective in managing congestive heart fail- 
ure and appear to represent the vasodilators of choice at 
present (81). They currently are the three angiotensin- 
converting enzyme inhibitors available in the United States. 
The benefit produced by these drugs underscores the con- 
cept that the renin-angiotensin-aldosterone system has over- 
shot in patients with congestive heart failure and can pro- 
duce adverse hemodynamic effects. It should be 
remembered that diuretics and arteriolar vasodilators acti- 
vate this system and thus help to set the stage for the use of 
angiotensin-converting enzyme inhibitors. The short-term 
administration of these agents to patients with congestive 
heart failure produces a reduction in blood pressure and 
systemic vascular resistance and a striking reduction in left 
and right atria1 pressures. This is accompanied by a modest 
increase in cardiac output (82). Of some importance is the 
ability of angiotensin-converting enzyme inhibitors to in- 
crease exercise tolerance in patients with congestive heart 
failure (83). This improvement in exercise tolerance occurs 
over a period of several weeks, which is different, for 
example, from the short-term improvement in exercise tol- 
erance that occurs with the potent inotropic agents such as 
dobutamine or the phosphodiesterase inhibitors (84). More 
important, this improvement in exercise tolerance appears to 
be accompanied by an improvement in patient well-being 
and quality of life. The angiotensin-converting enzyme in- 
hibitors have especially become popular because of their 
demonstrated effect in prolonging life in the CONSENSUS 
trial (85). In this trial, patients with severe heart failure 
(mostly functional class IV) had either an angiotensin- 
converting enzyme inhibitor (enalapril) or placebo added to 
their regimen; there was a reduction in mortality in the 
enalapril-treated group (Fig. 5). A review of some of the 
captopril data (86) suggests a similar beneficial effect on 
mortality. It is likely that all of the angiotensin-converting 
enzyme inhibitors will have generally similar effects, al- 
though their short-term effects may be slightly different, in 
part related to the time course of their action (87). 
Dosage. An important aspect of the angiotensin- 
converting enzyme inhibitors is their dose response relation 
(81). When one has achieved inhibition of converting en- 
zyme, one has reached the appropriate therapeutic dose. 
This makes it relatively easy to titrate the angiotensin- 
converting enzyme inhibitors to an appropriate level. One 
starts with a low dose to avoid or minimize hypotensive 
effects and then gradually works up to a standard dose. This 
would be approximately 25 mg three times daily of captopril, 
5 to 10 mg twice daily of enalapril and 10 to 20 mg once daily 
of lisinopril. The newest of these agents, lisinopril, is a 
long-acting angiotensin-converting enzyme inhibitor and will 
thus have the advantage of being given only once daily, 
which may well improve patient compliance (88). 
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Selection of drugs for new onset congestive failure. In the 
past a step-care approach to the management of heart failure 
has been suggested. This step-care approach generally in- 
cluded starting with a diuretic and then adding digoxin if 
necesary. This was followed by the addition of vasodilators 
if digoxin and diuretics were ineffective together. Recent 
studies (57), however, have suggested that the vasodilators 
may be appropriate alternatives to digoxin for first-line 
therapy. The following approach, therefore, is suggested for 
patients with new onset congestive heart failure (Table 3). If 
the patient has evidence of volume excess or systemic or 
pulmonary edema, it is likely that diuretics will be required 
as a permanent part of the therapy of these patients. It makes 
sense, therefore, to start with the diuretics as first-line 
therapy and then to add other drugs as appropriate. In 
patients with left ventricular dysfunction or early signs of 
congestive heart failure, there is important evidence that 
unloading therapy with the angiotensin-converting enzyme 
inhibitors may alter remodeling and slow the intrinsic decline 
in cardiac contractility (12). Thus, vasodilator therapy can 
be considered much earlier than in the past, and may prove 
useful in the earliest forms of heart failure to unload the 
ventricle. On the other hand, digoxin appears to be most 
effective in patients who have more severe heart failure (5 I ). 
The benefit of its use in mild heart failure is less certain. 
Thus, this approach would consider any of the three 
classes of drugs as potential first-line therapy in patients with 
heart failure. Additional classes would be added as needed 
because of their demonstrated additive effects. For example, 
digoxin added to captopril has been shown to improve 
hemodynamics in patients with congestive heart failure (89). 
Similarly, hydralazine as an arteriolar vasodilator when 
added to captopril has been shown to be beneficial in further 
improving cardiac output (90). 
Effect on survival. In selecting drugs one must remember 
that only the vasodilators have shown a prolongation of life 
in placebo-controlled trials (91). In the V-HEFT trial. the 
combination of hydralazine plus isosorbide dinitrate was 
effective in prolonging life in the treatment group as com- 
pared with the patients receiving placebo or prazosin (77). 
All had moderate heart failure and baseline therapy of 
digitalis and diuretics. In the CONSENSUS trial (85) enala- 
pril was effective in prolonging life in patients with severe 
heart failure (Fig. 5). Thus. vasodilators have been shown to 
prolong life in patients with both moderate and severe heart 
failure. Because of their potential benefit in mild heart 
failure, or even in left ventricular dysfunction, it appears that 
a vasodilator regimen may emerge as core therapy for 
patients with all stages of congestive heart failure. Because 
of their potential beneficial effects they should be used in 
patients with severe heart failure unless there are contrain- 
dications such as renal insufficiency. 
I = lnotropic Agent 
V = Vasodilator 
D = Diuretic 
II i 
LeH Ventricular Fllhng Pressure . 
Figure 6. Conceptual ventricular function curves showing the ef- 
fects of single and combined therapy for congestive heart failure. 
Note that the individual beneficial effects of each of the three classes 
of drugs are additive when additional drugs are given. This sets the 
stage for the use of all three classes of drugs to provide maximal 
beneficial hemodynamic effects in patients with congestive heart 
failure. 
Hemodynamic effects. In virtually all studies in which 
combination therapy with different classes of drugs has been 
used. it appears that their hemodynamic effects are generally 
additive. Thus, in patients with severe heart failure it makes 
good sense to consider the combination of diuretics, inotro- 
pit agents and vasodilators to maxmimize beneficial hemo- 
dynamic effects. This is conceptually shown in Figure 6. In 
general, therefore, one can start with any of the classes of 
drugs as suggested above and then gradually add other 
classes as the heart failure worsens so that patients are 
eventually receiving all three types of antifailure therapy. 
Antiarrhythmic Drugs 
The mode of death in patients with severe heart failure is 
sudden approximately 40% of the time (5). Studies (92) with 
Holter electrocardiographic (ECG) monitors in patients with 
congestive heart failure have demonstrated that arrhythmias 
occur in approximately 90% of patients and that non- 
sustained ventricular tachycardia or multifocal premature 
ventricular complexes are relatively common. The data 
suggest that arrhythmias add independently to an adverse 
prognosis in patients with congestive heart failure (93) 
although the level of left ventricular dysfunction remains the 
most important adverse prognostic factor. It has therefore 
been reasonable to consider some form of antiarrhythmic 
therapy in patients with severe heart failure and associated 
serious arrhythmias. The value of this therapy is uncertain at 
present. The following discussion represents potential direc- 
tions that one might take until more definitive data are 
available. 
Reduction of proarrhythmic factors. It seems prudent 
initially to reduce or eliminate all proarrhythmic factors (94) 
that can be recognized (Table 4). These might include 
adverse effects of inotropic agents, such as digitalis in the 
presence of hypokalemia. Electrolyte imbalance should be 
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Table 4. Proarrhythmic Factors in Congestive Heart Failure 
I. Arrhythmogenic effects of positive inotropic agents 
2. Electrolyte imbalance 
3. Ischemia 
4. High cathecholamines 
5. Myocardial damage 
6. Myocardial stretch 
7. Hypotension 
8. Proarrhythmic effects of antiarrhythmic agents 
corrected wherever possible. lschemia can be an important 
contributory factor to prognosis, and can be treated with 
appropriate anti-ischemic agents such as nitrates. High cat- 
echolamine levels may also contribute to arrhythmias. In 
patients with severe heart failure it would be difficult to 
consider using beta-blockers or calcium channel blockers as 
antianginal agents, although such therapy could be used in 
patients with less severe congestive heart failure. Because of 
the evidence that increased stretch might play a role in 
producing arrhythmias in heart failure, vasodilator therapy 
may be helpful in eliminating this proarrhythmic factor. 
Placebo-controlled trials with the angiotensin-converting en- 
zyme inhibitors have shown a reduction in premature ven- 
tricular complexes in patients with severe heart failure 
(5735). Although there was no reduction in sudden death in 
the CONSENSUS trial (85) it still may be that reduction of 
premature ventricular complexes with the angiotensin- 
converting enzyme inhibitors could be of benefit in some 
patients with excess arrhythmias. The mechanism of re- 
duced premature ventricular complexes with the angioten- 
sin-converting enzyme inhibitors is unknown. Factors that 
might contribute, however, would include an increase in 
serum potassium, which is frequently seen with the angio- 
tensin-converting enzyme inhibitors; unloading of the ven- 
tricle, which may reduce stretch-induced arrhythmias or 
ischemia; a decrease in myocardial oxygen consumption, 
which could also decrease episodes of ischemia; and a 
withdrawal of sympathetic tone. These or other factors may 
contribute to this beneficial antiarrhythmic effect. 
Indications for antiarrhythmic therapy. When all pro- 
arrhythmic factors have been ruled out and a patient with 
congestive heart failure still has serious arrhythmias the 
physician must make a decision whether to treat the arrhyth- 
mia. One must remember that, in general, antiarrhythmic 
therapy has a proarrhythmic effect that is seen in approxi- 
mately 10% of patients, a figure that may, in fact, be closer to 
20% in patients with severe heart failure (94). In addition, 
studies (95) have shown that the efficacy of antiarrhythmic 
agents appears to be proportionally less as the degree of heart 
failure increases. At the present time, we do not have any 
placebo-controlled trials to suggest that antiarrhythmic ther- 
apy can prolong life, although such trials are either underway 
or in the planning stage. The physician is therefore left to his 
best judgment in regard to antiarrhythmic therapy. 
Effect on survival. In a retrospective review (96) of the 
data in a group of patients whom we treated with potent oral 
inotropic agents (phosphodiesterase inhibitors) we noted 
that sudden death appeared to occur less often in patients 
treated with antiarrhythmic agents as those in patients not so 
treated. Cleland et al. (97) also suggested that the drug 
amiodarone may be effective in prolonging life in patients 
with severe heart failure and arrhythmias. Although such 
data are uncontrolled, they do suggest the possibility that 
antiarrhythmic drugs may be of some benefit. Certainly the 
toxic effects of amiodarone become less important in pa- 
tients with severe heart failure when life span is generally 
shortened. Until well controlled studies are available, how- 
ever, physician judgment must be used in the absence of firm 
data in determining whether to use antiarrhythmic therapy in 
selected patients. 
Summary 
In conclusion, we have learned a tremendous amount 
about the pathophysiology of congestive heart failure over 
the past 2 decades. One of the most important principles that 
has emerged is that compensatory mechanisms that are ini- 
tially helpful may subsequently become deleterious. Counter- 
acting these compensatory mechanisms has formed one of the 
most important therapeutic approaches to patients with con- 
gestive heart failure. Of the three classes of drugs available to 
treat congestive heart failure, the vasodilator drugs have 
emerged as the most important, especially because of their 
demonstrated ability to prolong life. Of the available vasodi- 
lator drugs, the angiotensin-converting enzyme inhibitors 
have emerged as the most important single class of drugs to 
consider in patients with heart failure. Because of the additive 
effects of all three classes of drugs, it is reasonable to start 
with one agent and then sequentially add others as required so 
that most patients with severe heart failure will be receiving a 
combination of a diuretic, an inotropic agent and a vasodilator 
drug. The role of antiarrhythmic agents is not settled as yet, 
although the prevalence of severe arrhythmias and sudden 
death suggests the possibility that these agents may be of 
benefit to some patients with congestive heart failure and 
serious arrhythmias. 
In looking to thefuture, it is clear that prevention of heart 
failure should be one of our most important goals as physi- 
cians. As with any disease, preventive measures are far 
more effective in the long run than is treating the end stage of 
the disease. Because coronary artery disease is the most 
common cause of congestive heart failure in the United 
States, preventive measures will be closely linked to the 
ability to control and alter risk factors in a way that will 
reduce the incidence of coronary disease and the damaging 
effects of myocardial infarction. Revascularization proce- 
dures both during acute infarction and in chronic coronary 
disease may also delay the adverse effects of myocardial 
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damage in this syndrome. Unloading agents early in the 
course of left ventricular dysfunction may also prove to be 
an effective way to delay the onset of heart failure. It is likely 
that this emphasis on prevention will, over time, produce 
greater benefit than the current benefit seen with the use of 
drugs in patients with established congestive heart failure. 
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